Infographic: Which Companies are Developing Ranibizumab Biosimilars?

Lucentis (ranibizumab) faces oncoming competition from 4 companies that are developing proposed biosimilars.

Related Content:

Ophthalmology

The European Union Gains Another Ranibizumab Biosimilar

In Sight: The Future of Biosimilars in Ophthalmology Care

AMCP Nexus Abstracts Investigate Adoption, Budget Impact of Biosimilars